Healthcare Resource Utilization (HCRU) and Costs of Poly(ADP-ribose) Polymerase Inhibitors (PARPi) as First-Line Maintenance (1LM) Treatment for Ovarian Cancer (OC)
Author(s)
Laura Moore-Schiltz, PhD1, Joseph Tkacz, MS1, Kathleen Wilson, MPH1, Jean A. Hurteau, MD2, Jonathan Lim, MSc3, Alin Kalayjian, MBA, PharmD3, John Hartman, PD, MA3.
1Inovalon, Bowie, MD, USA, 2GSK, Waltham, MA, USA, 3GSK, Upper Providence, PA, USA.
1Inovalon, Bowie, MD, USA, 2GSK, Waltham, MA, USA, 3GSK, Upper Providence, PA, USA.
OBJECTIVES: The objective of this real-world study was to examine HCRU and costs for patients with OC receiving 1LM PARPi monotherapy, as existing data are limited.
METHODS: The 100% Medicare Fee-for-Service database and MORE2 Registry of closed claims were leveraged for the present analyses. Key study inclusion criteria were ≥1 inpatient or ≥2 outpatient medical claims with an ICD-10-CM diagnosis code for ovarian, fallopian tube, or peritoneum cancer (collectively referred to as OC; January 1, 2017-June 30, 2022); initiated first-line (1L) platinum-based chemotherapy after the OC diagnosis; initiated 1LM PARPi monotherapy (niraparib, olaparib, or rucaparib) within 180 days of 1L platinum-based chemotherapy discontinuation (index date); and continuous enrollment during the 12 months preceding the OC diagnosis (baseline) through 30 days post-index. All HCRU and cost measures were assessed descriptively during the baseline and follow-up periods. Descriptive analyses were used to examine HCRU and costs over fixed time periods.
RESULTS: There were 646 eligible patients (mean [SD] age at index, 67.2 [11.7] years; 64.1% White; mean [SD] follow-up, 17.9 [12.2] months). Overall, 174 patients (26.9%) had commercial insurance, 378 (58.5%) had Medicare Fee-for-Service, and 63 (9.8%) had Managed Medicaid. In the 12 months before 1LM PARPi initiation, 496 patients (76.8%) had ≥1 hospitalization, 646 (100.0%) had ≥1 physician office/clinic visit, and 426 (65.9%) had ≥1 emergency room (ER) visit; mean (SD) total medical costs per patient were $75,813 ($54,029). In the 6 months after 1LM PARPi initiation, 100 patients (15.5%) had ≥1 hospitalization, 642 patients (99.4%) had ≥1 physician office/clinic visits, and 199 (30.8%) had ≥1 ER visit; mean [SD] total medical costs per patient were $15,277 ($22,036).
CONCLUSIONS: Results of this real-world analysis highlight that 1LM PARPi monotherapy use was associated with relatively low HCRU and mean medical costs in the 6 months after PARPi initiation.
METHODS: The 100% Medicare Fee-for-Service database and MORE2 Registry of closed claims were leveraged for the present analyses. Key study inclusion criteria were ≥1 inpatient or ≥2 outpatient medical claims with an ICD-10-CM diagnosis code for ovarian, fallopian tube, or peritoneum cancer (collectively referred to as OC; January 1, 2017-June 30, 2022); initiated first-line (1L) platinum-based chemotherapy after the OC diagnosis; initiated 1LM PARPi monotherapy (niraparib, olaparib, or rucaparib) within 180 days of 1L platinum-based chemotherapy discontinuation (index date); and continuous enrollment during the 12 months preceding the OC diagnosis (baseline) through 30 days post-index. All HCRU and cost measures were assessed descriptively during the baseline and follow-up periods. Descriptive analyses were used to examine HCRU and costs over fixed time periods.
RESULTS: There were 646 eligible patients (mean [SD] age at index, 67.2 [11.7] years; 64.1% White; mean [SD] follow-up, 17.9 [12.2] months). Overall, 174 patients (26.9%) had commercial insurance, 378 (58.5%) had Medicare Fee-for-Service, and 63 (9.8%) had Managed Medicaid. In the 12 months before 1LM PARPi initiation, 496 patients (76.8%) had ≥1 hospitalization, 646 (100.0%) had ≥1 physician office/clinic visit, and 426 (65.9%) had ≥1 emergency room (ER) visit; mean (SD) total medical costs per patient were $75,813 ($54,029). In the 6 months after 1LM PARPi initiation, 100 patients (15.5%) had ≥1 hospitalization, 642 patients (99.4%) had ≥1 physician office/clinic visits, and 199 (30.8%) had ≥1 ER visit; mean [SD] total medical costs per patient were $15,277 ($22,036).
CONCLUSIONS: Results of this real-world analysis highlight that 1LM PARPi monotherapy use was associated with relatively low HCRU and mean medical costs in the 6 months after PARPi initiation.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD154
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Oncology